ISRCTN78973763已完成不适用
Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy
Shanghai Proton and Heavy Ion Center0 个研究点目标入组 31 人开始时间: 2018年8月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/30683133
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Non-small cell lung cancer (NSCLC):
- •1.1. According to the following criteria of the American Association of Cancer staging version 7:
- •1.1.1. T1-2 (T1 indicates that the cancer is contained within the lungs and T2 indicates that either the cancer is 3-5 cm in size, or any of the following: the cancer involves the main airway but is not close to where the bronchus divides, the cancer involves the inner lining of the chest cavity, or that part/all of the lung has collapsed or is blocked)
- •1.1.2. N0-1 (N0 indicates no spread to lymph nodes, N1 indicates there are cancer cells in the lymph nodes)
- •1.1.3. M0 (no distant cancer spread found)
- •1.2. Medically inoperable or declined surgery
- •2. Longest diameters of primary tumour and hilar lymph node <5 cm
- •3. Pathologically confirmed NSCLC or clinically diagnosed as NSCLC with the Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) avid lung lesion
- •4. Diagnosed with NSCLC with CT scans by 2 senior radiologists independently
排除标准
- •1. Locally advanced or metastastic NSCLC at diagnosis
- •2. Previously received radiotherapy
- •3. Younger than 14 years of age
- •4. No signed informed consent
研究者
相似试验
尚未招募
不适用
Designing information for lung cancer patients in decision making.Patients presenting with a stage I non-small cell lung cancer (NSCLC).Patienten met stadium I niet kleincellige longkanker.NL-OMON2116225
已完成
不适用
tritional Assessment in Non-small Cell lung cancer patientslungcancerNon Small Cell Lung Cancer10038666NL-OMON50451Antoni van Leeuwenhoek Ziekenhuis100
已完成
不适用
Streamlining Staging of Lung cancer with Whole Body MRICancerISRCTN50436483niversity College London (UK)353
已完成
2 期
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNon Small Cell Lung CancerNCT02716311Intergroupe Francophone de Cancerologie Thoracique118
招募中
1 期
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)NCT05099172Bayer400